Correction to “Severe Thiopurine‐Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient ith the NUDT15 *1/*6 Genotype: A Brief Report”

J. Fry, E. C. Boone, W. Y. Wang, et al., “ Severe Thiopurine-Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient With the NUDT15 *1/*6 Genotype: A Brief Report,” Clinical and Translational Science 19, no. 6 (2026): e70639, https://doi.org/10.1111/cts.70639. In the article cited above, the data points in Figure 2 are not visible beneath the green and red bars. FIGURE 2White blood cell (WBC) count and absolute neutrophil count (ANC) in the Maintenance phase of chemotherapy with time points marked where mercaptopurine (6MP) was held, resumed, or reduced in dose (A). 6-TGN and 6-MMP metabolites in the Maintenance phase of chemotherapy with time points marked where mercaptopurine (6MP) was held, resumed, or reduced in dose (B). During Maintenance, 6MP dosing was adjusted based on ANC and platelet counts, per protocol.